Nitric oxide and cancer therapy: The emperor has NO clothes

Current Pharmaceutical Design

Volumn 16, Issue 4, 2010, Pages 381-391

  Hickok, Jason R ^a   Thomas, Douglas D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cancer; Chemotherapy; Metastasis; Nitric oxide; Nitric oxide synthase

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GT 049; GT 094; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; SC 51; UNCLASSIFIED DRUG; NITRIC OXIDE DONOR;

ANTINEOPLASTIC ACTIVITY; BREAST ADENOCARCINOMA; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; ENZYME INHIBITION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS;

ANIMALS; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE;

EID: 77949464599     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790232149     Document Type: Review

References (97)

1. Ignarro L. Nitric Oxide Biology and Pathobiology. New York: Academic Press 2000.
2. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-56.
3. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007; 27: 317-52.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008; 45: 18-31.
6. Iwasaki T, Higashiyama M, Kuriyama K, Sasaki A, Mukai M, Shinkai K, et al. NG-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn J Cancer Res 1997; 88: 861-6.
7. Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, et al. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res 2008; 10: R44.
8. Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis 2009; 15: 8-17.
9. Blavier L, Lazaryev A, Dorey F, Shackleford GM, DeClerck YA. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res 2006; 66: 2691-9.
10. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
11. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001; 61: 1320-6.
12. Christofori G. New signals from the invasive front. Nature 2006; 441: 444-50.
13. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
14. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.
15. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8.
16. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
17. Edlund M, Sung SY, Chung LW. Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem 2004; 91: 686-705.
18. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev 2008; 34: 247-58.
19. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988; 81: 1109-12.
20. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106: 1624-33.
21. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479-85.
22. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2: 1352-8.
23. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 7737-42.
24. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999; 91: 80-5.
25. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6: 4768-75.
26. Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 2005; 41: 265-71.
27. Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A, et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 2004; 92: 806-12.
28. Connelly ST, Macabeo-Ong M, Dekker N, Jordan RC, Schmidt BL. Increased nitric oxide levels and iNOS over-expression in oral squamous cell carcinoma. Oral Oncol 2005; 41: 261-7.
29. Brennan PA, Dennis S, Poller D, Quintero M, Puxeddu R, Thomas GJ. Inducible nitric oxide synthase: correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head Neck 2008; 30: 208-14.
30. Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, et al. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res 2008; 68: 7130-6.
31. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256: 668-70.
32. Ahn B, Ohshima H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res 2001; 61: 8357-60.
33. Scott DJ, Hull MA, Cartwright EJ, Lam WK, Tisbury A, Poulsom R, et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology 2001; 121: 889-99.
34. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002; 62: 165-70.
35. Kawamori T, Takahashi M, Watanabe K, Ohta T, Nakatsugi S, Sugimura T, et al. Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Cancer Lett 2000; 148: 33-7.
36. Harada K, Supriatno, Kawaguchi S, Tomitaro O, Yoshida H, Sato M. Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells. In Vivo 2004; 18: 449-55.
37. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181: 1333-43.
38. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995; 92: 4392-6.
39. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008; 19: 65-7.
40. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54.
41. Schmucker D, Clemens JC, Shu H, Worby CA, Xiao J, Muda M, et al. Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell 2000; 101: 671-84.
42. Decker NK, Abdelmoneim SS, Yaqoob U, Hendrickson H, Hormes J, Bentley M, et al. Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver. Am J Pathol 2008; 173: 1002-12.
43. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000; 86: 30-9.
44. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155: 1381-90.
45. Zhou J, Schmid T, Brune B. HIF-1α and p53 as targets of NO in affecting cell proliferation, death and adaptation. Curr Mol Med 2004; 4: 741-51.
46. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-9.
47. Tanriover N, Ulu MO, Isler C, Durak H, Oz B, Uzan M, et al. Neuronal nitric oxide synthase expression in glial tumors: correlation with malignancy and tumor proliferation. Neurol Res 2008; 30: 940-4.
48. Broholm H, Rubin I, Kruse A, Braendstrup O, Schmidt K, Skriver EB, et al. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol 2003; 22: 273-81.
49. Weinberg RA. The Biology of Cancer, USA: Garland Science 2007.
50. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 1992; 67: 166-74.
51. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
52. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002; 44: 143-61.
53. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.
54. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19: 711-21.
55. Gauthier N, Lohm S, Touzery C, Chantome A, Perette B, Reveneau S, et al. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis 2004; 25: 1559-65.
56. Mehibel M, Singh S, Chinje EC, Cowen RL, Stratford IJ. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N). Mol Cancer Ther 2009; [Epub ahead of print].
57. Stuehr DJ, Santolini J, Wang ZQ, Wei CC, Adak S. Update on mechanism and catalytic regulation in the NO synthases. J Biol Chem 2004; 279: 36167-70.
58. Thomas DD, Liu X, Kantrow SP, Lancaster JR, Jr. The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci USA 2001; 98: 355-60.
59. Bellamy TC, Wood J, Garthwaite J. On the activation of soluble guanylyl cyclase by nitric oxide. Proc Natl Acad Sci USA 2002; 99: 507-10.
60. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004; 101: 8894-9.
61. . concentration in vivo? Nitric Oxide 2009; 21: 92-103.
62. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
63. Lymar SV, Khairutdinov RF, Hurst JK. Hydroxyl radical formation by O-O bond homolysis in peroxynitrous acid. Inorg Chem 2003; 42: 5259-66.
64. Thomas DD, Ridnour LA, Espey MG, Donzelli S, Ambs S, Hussain SP, et al. Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem 2006; 281: 25984-93.
65. Elvin P, Garner AP. Tumour invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol 2005; 5: 374-81.
66. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84: 1424-31.
67. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998; 17: 279-84.
68. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003; 5: 711-9.
69. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160: 267-77.
70. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003; 100: 15901-5.
71. . and related redox species in biological systems. Methods Enzymol 2002; 359: 84-105.
72. . release: contemporary aspects in biological and medicinal chemistry. Free Radic Biol Med 2004; 37: 1122-43.
73. Hogg N. Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med 2000; 28: 1478-86.
74. .)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem 2005; 5: 625-36.
75. Robinson KM, Beckman JS. Synthesis of peroxynitrite from nitrite and hydrogen peroxide. Methods Enzymol 2005; 396: 207-14.
76. Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 1989; 14 (Suppl 11): S13-22.
77. Miranda KM, Dutton AS, Ridnour LA, Foreman CA, Ford E, Paolocci N, et al. Mechanism of aerobic decomposition of Angeli's salt (sodium trioxodinitrate) at physiological pH. J Am Chem Soc 2005; 127: 722-31.
78. Sandau KB, Faus HG, Brune B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000; 278: 263-7.
79. Sandau KB, Fandrey J, Brune B. Accumulation of HIF-1α under the influence of nitric oxide. Blood 2001; 97: 1009-15.
80. Cui X, Zhang J, Ma P, Myers DE, Goldberg IG, Sittler KJ, et al. cGMP-independent nitric oxide signaling and regulation of the cell cycle. BMC Genomics 2005; 6: 151.
81. Turpaev K, Bouton C, Diet A, Glatigny A, Drapier JC. Analysis of differentially expressed genes in nitric oxide-exposed human monocytic cells. Free Radic Biol Med 2005; 38: 1392-400.
82. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992; 107: 1092-5.
83. Coulter JA, McCarthy HO, Xiang J, Roedl W, Wagner E, Robson T, et al. Nitric oxide - a novel therapeutic for cancer. Nitric Oxide 2008; 19: 192-8.
84. Orucevic A, Lala PK. Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice. Cancer Immunol Immunother 1996; 42: 38-46.
85. Inano H, Onoda M. Nitric oxide produced by inducible nitric oxide synthase is associated with mammary tumorigenesis in irradiated rats. Nitric Oxide 2005; 12: 15-20.
86. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009; 9: 442-58.
87. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio- resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008; 19: 205-16.
88. Chakrapani H, Wilde TC, Citro ML, Goodblatt MM, Keefer LK, Saavedra JE. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound. Bioorg Med Chem 2008; 16: 2657-64.
89. Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, et al. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007; 110: 709-18.
90. . chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo. Mol Cancer Ther 2007; 6: 2230-9.
91. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA 2005; 102: 17207-12.
92. Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, et al. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007; 50: 2424-31.
93. Dunlap T, Chandrasena RE, Wang Z, Sinha V, Thatcher GR. Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. Chem Res Toxicol 2007; 20: 1903-12.
94. . donor functionality. Nitric Oxide 2008; 19: 115-24.
95. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Varella EA, Nicolaides DN. Recent developments in the chemistry and in the biological applications of amidoximes. Curr Pharm Des 2008; 14(10): 1001-47.
96. Motilva V, Talero E, Calvo JR, Villegas I, Alarcon-de-la-Lastra C, Sanchez-Fidalgo S. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities. Curr Pharm Des 2008; 14(1): 71-95.
97. Sullivan R, Graham CH. Chemosensitization of cancer by nitric oxide. Curr Pharm Des 2008; 14(11): 1113-23.